$0.62
+0.03 (+4.47%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BRNS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 5 with posted results
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| VTP-1000 in Adults With Celiac DiseaseNCT06310291Treatment Emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest (AESIs)Randomized · Quadruple-masked · Treatment | Early Phase 1 | Recruiting | Biological: VTP-1000 · Other: Matched Placebo | Celiac Disease | 45 | Nov 2026 | ≤ 103 d | 2026-06-18 |
| Efficacy of VTP-300 in Chronic Hepatitis B InfectionNCT05343481The incidence of participants with a greater than 1 log HBsAgRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: ChAdOx1-HBV, MVA-HBV, Nivolumab | Chronic Hepatitis B | 121 | 2026-01-13actual | — | 2026-04-30 |
| Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate CancerNCT05617040results2025-11-10The Safety of VTP-850 Prime-boost Regimens, With the Booster Dose Administered Either IM or IV, and the Recommended Phase 2 Regimen (RP2R)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns. | Biological: ChAdOx1-PCAQ, MVA-PCAQ | Prostate Cancer | 22 | 2025-02-05actual | — | 2025-11-10 |
| Prime-boost Vaccine Study in Women With Low-grade Cervical HPV LesionsNCT04607850Incidence of adverse events to measure safety and reactogenicityRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Biological: ChAdOx1-HPV, MVA-HPV, Placebo | HPV Infection, CIN1 | 108 | 2024-01-16actual | — | 2025-08-28 |
| First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBVNCT04778904results2024-08-13The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study VaccinationRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: ChAdOx1-HBV, MVA-HBV, Nivolumab | Hepatitis B | 55 | 2023-02-24actual | — | 2024-08-13 |
| First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB InfectionNCT04297917results2025-08-12Incidence of Safety and Reactogenicity Events: Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: ChAdOx1-HBV | Hepatitis B, Healthy | 47 | 2022-05-23actual | — | 2025-08-12 |
| Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge ModelNCT03883113results2021-03-18Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCRRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015) | Influenza | 145 | 2019-12-16actual | — | 2021-03-18 |
| Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in AdultsNCT03880474results2021-04-26Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The trial is being stopped for futility. Season 2 cancelled. | Biological: MVA-NP+M1 · Drug: Saline | Influenza | 2,364 | 2019-10-15actual | — | 2021-04-26 |
| Improved Novel VaccIne CombinaTion InflUenza StudyNCT03300362Number of days with moderate or severe influenza-like symptomsRandomized · Single-masked · Prevention | Phase 2 | Terminatedsponsor's stated reason: Change to recommended season flu vaccine in UK | Drug: Seasonal influenza vaccine, MVA-NP+M1, Sodium chloride | Influenza | 862 | 2018-10-31actual | — | 2018-11-23 |
| A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1NCT03277456Measure of local reactogenicity following intramuscular injection of MVA-NP+M1Open-label · Prevention | Early Phase 1 | Completed | Biological: MVA-NP+M1 | Human Volunteers | 6 | 2017-11-02actual | — | 2017-11-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19